Patents by Inventor Hans Lilja

Hans Lilja has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS RELATED TO DIAGNOSIS OF PROSTATE CANCER
    Publication number: 20230393137
    Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.
    Type: Application
    Filed: May 30, 2023
    Publication date: December 7, 2023
    Applicant: OPKO Diagnostics, LLC
    Inventors: Vincent Linder, David Steinmiller, Kim Pettersson, Timo Lovgren, Hans Lilja, Andrew J. Vickers, Peter T. Scardino
  • Compositions and methods related to diagnosis of prostate cancer
    Patent number: 11761962
    Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: September 19, 2023
    Assignee: OPKO Diagnostics, LLC
    Inventors: Vincent Linder, David Steinmiller, Kim Pettersson, Timo Lovgren, Hans Lilja, Andrew J. Vickers, Peter T. Scardino
  • SYSTEMS FOR PROVIDING A PROBABILITY OF PROSTATE CANCER RISK AND/OR PROSTATE GLAND VOLUME, AND RELATED METHODS
    Publication number: 20220399121
    Abstract: Aspects of the disclosure relate to improved methods and systems for active surveillance of subject having non-aggressive prostate cancer.
    Type: Application
    Filed: May 2, 2022
    Publication date: December 15, 2022
    Applicant: OPKO Diagnostics, LLC
    Inventors: Yan Dong, Andrew J. Vickers, Daniel Sjoberg, Peter T. Scardino, Hans Lilja
  • Methods and apparatuses for conducting analyses
    Patent number: 10672503
    Abstract: Methods and apparatuses for conducting analyses are provided.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 2, 2020
    Assignees: OPKO Diagnostics, LLC, Oy Arctic Partners Ab
    Inventors: Andrew J. Vickers, Peter T. Scardino, Hans Lilja, Vincent Linder, David Steinmiller
  • METHODS AND APPARATUSES FOR PREDICTING RISK OF PROSTATE CANCER AND PROSTATE GLAND VOLUME
    Publication number: 20170168060
    Abstract: Methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided. More particularly, this disclosure relates to methods and apparatuses for providing the models and employing the models for predicting risk of prostate cancer and/or predicting prostate gland volume. The methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided using, at least in part, information from a panel of kallikrein markers.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Applicants: OPKO Diagnostics, LLC, Oy Arctic Partners Ab
    Inventors: Andrew J. Vickers, Peter T. Scardino, Hans Lilja, Vincent Linder, David Steinmiller
  • Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
    Patent number: 9672329
    Abstract: Methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided. More particularly, this disclosure relates to methods and apparatuses for providing the models and employing the models for predicting risk of prostate cancer and/or predicting prostate gland volume. The methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided using, at least in part, information from a panel of kallikrein markers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: June 6, 2017
    Assignees: OPKO Diagnostics, LLC, Oy Arctic Partners Ab
    Inventors: Andrew J. Vickers, Peter T. Scardino, Hans Lilja, Vincent Linder, David Steinmiller
  • METHODS AND APPARATUSES FOR CONDUCTING ANALYSES
    Publication number: 20170091379
    Abstract: Methods and apparatuses for conducting analyses are provided.
    Type: Application
    Filed: June 29, 2016
    Publication date: March 30, 2017
    Applicants: OPKO Diagnostics, LLC, Oy Arctic Partners Ab
    Inventors: Andrew J. Vickers, Peter T. Scardino, Hans Lilja, Vincent Linder, David Steinmiller
  • METHODS AND APPARATUSES FOR CONDUCTING ANALYSES
    Publication number: 20170091380
    Abstract: Methods and apparatuses for conducting analyses are provided.
    Type: Application
    Filed: June 29, 2016
    Publication date: March 30, 2017
    Inventors: Andrew J. Vickers, Peter T. Scardino, Hans Lilja, Vincent Linder, David Steinmiller
  • COMPOSITIONS AND METHODS FOR ACTIVE SURVEILLANCE OF PROSTATE CANCER
    Publication number: 20170089904
    Abstract: Aspects of the disclosure relate to improved methods and systems for active surveillance of subject having non-aggressive prostate cancer.
    Type: Application
    Filed: April 29, 2016
    Publication date: March 30, 2017
    Applicant: OPKO Diagnostics, LLC
    Inventors: Yan Dong, Andrew J. Vickers, Daniel Sjoberg, Peter T. Scardino, Hans Lilja
  • COMPOSITIONS AND METHODS FOR ACTIVE SURVEILLANCE OF PROSTATE CANCER
    Publication number: 20160320394
    Abstract: Aspects of the disclosure relate to improved methods and systems for active surveillance of subject having non-aggressive prostate cancer.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 3, 2016
    Applicant: OPKO DIAGNOSTICS, LLC
    Inventors: YAN DONG, ANDREW J. VICKERS, DANIEL SJOBERG, PETER T. SCARDINO, HANS LILJA
  • COMPOSITIONS AND METHODS RELATED TO DIAGNOSIS OF PROSTATE CANCER
    Publication number: 20160025732
    Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.
    Type: Application
    Filed: March 27, 2015
    Publication date: January 28, 2016
    Applicant: OPKO Diagnostics, LLC
    Inventors: Vincent Linder, David Steinmiller, Kim Pettersson, Timo Lovgren, Hans Lilja, Andrew J. Vickers, Peter T. Scardino
  • Activation of peptide prodrugs by hK2
    Patent number: 8669231
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 11, 2014
    Assignee: GenSpera, Inc.
    Inventors: Samuel R. Denmeade, John Tod Isaacs, Hans Lilja
  • Activation of peptide prodrugs by hK2
    Patent number: 8450280
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: May 28, 2013
    Assignee: GenbSpera, Inc.
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
  • Activation of Peptide Prodrugs by hK2
    Publication number: 20120309692
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Application
    Filed: May 16, 2012
    Publication date: December 6, 2012
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
  • Activation of Peptide Prodrugs by HK2
    Publication number: 20110245147
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Application
    Filed: January 10, 2011
    Publication date: October 6, 2011
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
  • Activation of peptide prodrugs by hK2
    Patent number: 7906477
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: March 15, 2011
    Assignee: Genspera, Inc.
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
  • Antibody, immunoassay and method for prostate cancer detection
    Patent number: 7872104
    Abstract: This invention concerns an antibody which binds with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA. This invention further concerns an immunoassay and a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and/or healthy male subjects without PCa, patients with aggressive PCa from patients with indolent PCa and/or patients with clinically localized and/or organ confined PCa from patients with extraprostatic extension of PCa and/or PCa with metastatic spread to lymph nodes or bone marrow using said antibody.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: January 18, 2011
    Assignee: Arctic Partners Oy AB
    Inventors: Kim Pettersson, Hans Lilja, Timo Lövgren, Pauliina Niemelä
  • Activation of peptide prodrugs by hK2
    Publication number: 20080247950
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Application
    Filed: March 15, 2007
    Publication date: October 9, 2008
    Applicant: Genspera, Inc.
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
  • Activation of peptide prodrugs by hk2
    Publication number: 20060217317
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Application
    Filed: November 18, 2003
    Publication date: September 28, 2006
    Inventors: Samuel Denmeade, John Isaacs, Hans Lilja
  • Activation of peptide prodrugs by hK2
    Publication number: 20060183689
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Application
    Filed: August 24, 2005
    Publication date: August 17, 2006
    Inventors: Samuel Denmeade, John Isaacs, Hans Lilja